When tested at a concentration of 10 pmol/l, both GLP-1(736) and GLP-1(936) inhibited glucagon secretion at 1 mmol/l glucose by ~50% (ESM Fig
Compounded injectables undergo the same sterility and potency testing as brand medications, and they're available without insurance across all 50 states
For those with hypermobility and EDS specifically, Id flag the following as the minimum due diligence before starting these medications: A thorough GI history and ideally gastric emptying assessment if theres any existing dysmotility Baseline muscle mass measurement (DEXA or similar) given the sarcopenia risk A clear plan for high-protein diet and resistance-based exercise to mitigate muscle loss Baseline bone density if theres any existing concern Consideration of the nutritional picture specific to hypermobility, since these drugs can affect appetite and nutrient absorption A conversation specifically about MCAS if thats a feature of your presentation The medication options for hypermobility and EDS are limited and often unsatisfying, and its entirely understandable why people are looking at something new with genuine curiosity
Frequently Asked Questions GLP-1 microdosing chart for beginners
Our weight loss program has always used FDA-approved semaglutide and tirzepatide, so the 503B rule doesn't touch our patients' supply
Roberto Olivardia, clinical psychologist and lecturer at Harvard Medical School, whose research focuses on body image distortion
